Profound Medical Corp. (PROF) Research

Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.

Market snapshot

Symbol
PROF
Price
$6.87
Day change
+4.57%
Market cap
$206.2M
P/E ratio
-6.37x
52-week range
3.76-8.95
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months
Analyst price target
$12.00

Peer companies

  • Armata Pharmaceuticals, Inc. (ARMP)
  • Anteris Technologies Global Corp. (AVR)
  • Perspective Therapeutics, Inc. (CATX)
  • LENSAR, Inc. (LNSR)
  • MaxCyte, Inc. (MXCT)
  • Nano-X Imaging Ltd. (NNOX)
  • Owlet, Inc. (OWLT)
  • Prenetics Global Limited (PRE)

Recent insider activity

  • Menawat Arun Swarup — P-Purchase (12027 shares) on 2025-05-16
  • Menawat Arun Swarup — P-Purchase (10003 shares) on 2025-05-15
  • HOFER MICHAEL — S-Sale (40000 shares) on 2012-12-20
  • HOFER MICHAEL — P-Purchase (40000 shares) on 2012-12-18
  • TEJADA FRED — P-Purchase (500000 shares) on 2012-06-19

Open Profound Medical Corp. (PROF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.